CA2403630C - Methods for inhibiting angiogenesis and tumor growth - Google Patents

Methods for inhibiting angiogenesis and tumor growth Download PDF

Info

Publication number
CA2403630C
CA2403630C CA002403630A CA2403630A CA2403630C CA 2403630 C CA2403630 C CA 2403630C CA 002403630 A CA002403630 A CA 002403630A CA 2403630 A CA2403630 A CA 2403630A CA 2403630 C CA2403630 C CA 2403630C
Authority
CA
Canada
Prior art keywords
compound
mmp2
compounds
integrin
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002403630A
Other languages
English (en)
French (fr)
Other versions
CA2403630A1 (en
Inventor
Dale L. Boger
David A. Cheresh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Priority to CA002659030A priority Critical patent/CA2659030A1/en
Publication of CA2403630A1 publication Critical patent/CA2403630A1/en
Application granted granted Critical
Publication of CA2403630C publication Critical patent/CA2403630C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002403630A 2000-03-27 2001-03-27 Methods for inhibiting angiogenesis and tumor growth Expired - Fee Related CA2403630C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002659030A CA2659030A1 (en) 2000-03-27 2001-03-27 Methods for inhibiting angiogenesis and tumor growth

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19226000P 2000-03-27 2000-03-27
US60/192,260 2000-03-27
PCT/US2001/009785 WO2001072297A1 (en) 2000-03-27 2001-03-27 Methods for inhibiting angiogenesis and tumor growth

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002659030A Division CA2659030A1 (en) 2000-03-27 2001-03-27 Methods for inhibiting angiogenesis and tumor growth

Publications (2)

Publication Number Publication Date
CA2403630A1 CA2403630A1 (en) 2001-10-04
CA2403630C true CA2403630C (en) 2009-05-26

Family

ID=22708924

Family Applications (3)

Application Number Title Priority Date Filing Date
CA002403630A Expired - Fee Related CA2403630C (en) 2000-03-27 2001-03-27 Methods for inhibiting angiogenesis and tumor growth
CA002659030A Abandoned CA2659030A1 (en) 2000-03-27 2001-03-27 Methods for inhibiting angiogenesis and tumor growth
CA2403871A Expired - Fee Related CA2403871C (en) 2000-03-27 2001-03-27 Inhibition of angiogenesis and tumor growth

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA002659030A Abandoned CA2659030A1 (en) 2000-03-27 2001-03-27 Methods for inhibiting angiogenesis and tumor growth
CA2403871A Expired - Fee Related CA2403871C (en) 2000-03-27 2001-03-27 Inhibition of angiogenesis and tumor growth

Country Status (15)

Country Link
EP (2) EP1272173A4 (pl)
JP (2) JP2003528850A (pl)
KR (2) KR100767616B1 (pl)
CN (2) CN1229339C (pl)
AU (4) AU2001249499B2 (pl)
CA (3) CA2403630C (pl)
CZ (2) CZ20023510A3 (pl)
HU (2) HUP0301621A3 (pl)
MX (2) MXPA02009504A (pl)
NO (2) NO20024576L (pl)
PL (2) PL205134B1 (pl)
RU (2) RU2269339C2 (pl)
SK (2) SK14852002A3 (pl)
WO (2) WO2001072297A1 (pl)
ZA (2) ZA200208628B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2235611B2 (es) * 2003-07-25 2006-07-16 Universidade De Santiago De Compostela Metodo cuantitativo para la deteccion de yesotoxinas en productos pesqueros basado en la activacion que producen en las fosfodiesterasas.
UA82561C2 (uk) 2003-10-23 2008-04-25 Оцука Фармасьютикалз Ко., Лтд. Стерильна ін'єкційна композиція арипіпразолу з контрольованим вивільненням, спосіб її виготовлення та спосіб лікування шизофренії
RU2287341C1 (ru) * 2005-03-01 2006-11-20 Автономная некоммерческая организация Научно-технический центр "Фармбиопресс" Ингибитор ангиогенеза, антиангиогенная фармацевтическая композиция на его основе и способ лечения злокачественных новообразований
SI2170279T1 (en) 2007-07-31 2018-04-30 Otsuka Pharmaceutical Co., Ltd. Methods for producing aripiprazole suspension and freeze-dried formulation
RU2404794C2 (ru) * 2008-11-27 2010-11-27 Государственное образовательное учреждение высшего профессионального образования Московская медицинская академия им. И.М. Сеченова Федерального агентства по здравоохранению и социальному развитию (ГОУВПО ММА им. И.М. Сеченова Росздрава) Вагинальные суппозитории для лечения рака шейки матки

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311286D0 (en) * 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
JPH05125029A (ja) * 1991-11-06 1993-05-21 Yamanouchi Pharmaceut Co Ltd 新規なアミド化合物又はその塩
GB9308695D0 (en) * 1993-04-27 1993-06-09 Celltech Ltd Peptidyl derivatives
UA44258C2 (uk) * 1993-10-15 2002-02-15 Рон-Пуленк Рорер Фармасьютікалз Інк. Антитромботичні азациклоалкілалканоілпептиди та псевдопептиди, фармацевтична композиція, що їх містить, спосіб профілактики або лікування тромбозу у ссавців (варіанти)
GB9405076D0 (en) * 1994-03-16 1994-04-27 Inst Of Ophtalmology A medical use of matrix metalloproteinase inhibitors
AUPO104496A0 (en) * 1996-07-17 1996-08-08 Biomolecular Research Institute Limited Angiogenic inhibitory compounds
JP2002514180A (ja) * 1996-09-04 2002-05-14 ワーナー―ランバート・コンパニー マトリックスメタロプロテイナーゼを阻害するための化合物およびその方法
EP0968423A4 (en) * 1997-02-07 2002-10-30 Scripps Research Inst CONVERGENT SYNTHESIS OF A COMBINATORY LIBRARY
JP2002509881A (ja) * 1998-03-27 2002-04-02 ジェネンテク・インコーポレイテッド Ｃｄ１１／ｃｄ１８接着レセプター媒介疾患の治療用アンタゴニスト

Also Published As

Publication number Publication date
NO20024576L (no) 2002-11-20
AU2001249499B2 (en) 2005-04-21
PL358272A1 (pl) 2004-08-09
HUP0301621A2 (hu) 2003-09-29
NO328969B1 (no) 2010-06-28
KR20020084258A (ko) 2002-11-04
CA2659030A1 (en) 2001-10-04
EP1272173A4 (en) 2006-05-03
CA2403871A1 (en) 2001-10-04
CN1229339C (zh) 2005-11-30
HUP0301621A3 (en) 2009-06-29
KR100776185B1 (ko) 2007-11-16
NO20024576D0 (no) 2002-09-24
AU5101801A (en) 2001-10-08
CZ20023509A3 (cs) 2003-06-18
NO20024578L (no) 2002-11-20
SK14842002A3 (sk) 2003-04-01
CN1245967C (zh) 2006-03-22
AU2001251018B2 (en) 2005-12-01
ZA200208626B (en) 2004-02-16
CA2403871C (en) 2010-05-11
EP1272173A1 (en) 2003-01-08
AU4949901A (en) 2001-10-08
WO2001072297A1 (en) 2001-10-04
NO20024578D0 (no) 2002-09-24
PL205134B1 (pl) 2010-03-31
ZA200208628B (en) 2004-02-12
JP2003528850A (ja) 2003-09-30
CN1429106A (zh) 2003-07-09
SK14852002A3 (sk) 2003-06-03
KR100767616B1 (ko) 2007-10-18
MXPA02009510A (es) 2003-05-21
HUP0301797A3 (en) 2010-09-28
EP1276713A1 (en) 2003-01-22
PL366316A1 (pl) 2005-01-24
CA2403630A1 (en) 2001-10-04
JP2003528140A (ja) 2003-09-24
EP1276713A4 (en) 2006-05-03
RU2276133C2 (ru) 2006-05-10
CN1441777A (zh) 2003-09-10
CZ20023510A3 (cs) 2003-03-12
WO2001072699A1 (en) 2001-10-04
HUP0301797A2 (hu) 2003-09-29
MXPA02009504A (es) 2003-05-21
RU2269339C2 (ru) 2006-02-10
KR20020091156A (ko) 2002-12-05
RU2002128751A (ru) 2004-03-10

Similar Documents

Publication Publication Date Title
JP2007521259A (ja) 軟部肉腫治療剤
WO2001034594A1 (en) Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors
KR101982669B1 (ko) Ape1 매개된 질환을 치료하기 위한 퀴논 화합물
AU2006235835B2 (en) Non-covalent inhibitors of urokinase and blood vessel formation
CA2403630C (en) Methods for inhibiting angiogenesis and tumor growth
EP1284265A1 (en) Benzothiophene derivatives and medicinal use thereof
US7368478B2 (en) Methods for inhibiting angiogenesis and tumor growth
AU2001249499A1 (en) Methods for inhibiting angiogenesis and tumor growth
AU2001251018A1 (en) Inhibition of angiogenesis and tumor growth
US6803383B2 (en) Inhibition of angiogenesis and tumor growth
CN108794358A (zh) 取代苯磺酰基类化合物及其制备药物的用途
JP2002505281A (ja) 炎症細胞抑制剤

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed